**FOI Ref: 6006**

**Category(ies): Clinical - Drugs**

**Subject: Biologic and Biosimilar Products**

**Date Received: 06/09/2021**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Q1. Could you please provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:* Abatacept [Orencia]
* Adalimumab [Humira]
* Adalimumab Biosimilars
* Apremilast [Otezla]
* Baricitinib [Olumiant]
* Certolizumab [Cimzia]
* Etanercept [Enbrel]
* Etanercept Biosimilars
* Filgotinib [Jyseleca]
* Golimumab [Simponi]
* Guselkumab [Tremfya]
* Infliximab [Remicade]
* Infliximab Biosimilars
* Ixekizumab [Taltz]
* Risankizumab [Skyrizi]
* Rituximab [MabThera]
* Rituximab Biosimilars
* Sarilumab [Kevzara]
* Secukinumab [Cosentyx]
* Tocilizumab [Ro Actemra]
* Tofacitinib [Xeljanz]
* Upadacitinib [Rinvoq]
* Ustekinumab [Stelara]

  | 25<51050317924601000130130001001137<5<5<5**The Trust considers that information you have requested would in some instances where very low volumes exist, potentially identify an individual and constitutes sensitive personal information. It is therefore exempt under section 40 (2) of the Freedom of Information Act and will not be released as this will likely contravene the 1st (used fairly, lawfully and transparently) and 6th (handled in a way that ensures appropriate security, including protection against unlawful or unauthorised processing, access, loss destruction or damage) data protection principles. Also, Data Protection Act Principle 1 state that when processing sensitive personal information, at least one of the conditions in Schedule 3 is met. The section 40 exemption is an absolute exemption and as such no public interest test should be applied.** |
|  Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs. * Abatacept [Orencia]
* Adalimumab [Humira]
* Adalimumab Biosimilars
* Apremilast [Otezla]
* Certolizumab [Cimzia]
* Etanercept [Enbrel]
* Etanercept Biosimilars
* Golimumab [Simponi]
* Guselkumab [Tremfya]
* Infliximab [Remicade]
* Infliximab Biosimilars
* Ixekizumab [Taltz]
* Risankizumab [Skyrizi]
* Secukinumab [Cosentyx]
* Tofacitinib [Xeljanz]
* Upadacitinib [Rinvoq]
* Ustekinumab [Stelara]
 | Unable to identify from reporting systems |